Рынок заболеваний, связанных с IgG4, в Северной Америке – тенденции отрасли и прогноз до 2028 года

Запрос на TOC Запрос на TOC Обратиться к аналитику Обратиться к аналитику Купить сейчас Купить сейчас Узнать перед покупкой Узнать перед покупкой Бесплатный пример отчета Бесплатный пример отчета

Рынок заболеваний, связанных с IgG4, в Северной Америке – тенденции отрасли и прогноз до 2028 года

  • Healthcare
  • Published Report
  • Oct 2021
  • North America
  • 350 Pages
  • Количество таблиц: 67
  • Количество рисунков: 39

North America Igg4 Related Disease Market

Размер рынка в млрд долларов США

CAGR :  % Diagram

Diagram Прогнозируемый период
2021 –2028
Diagram Размер рынка (базовый год)
USD 1,856.39 Million
Diagram Размер рынка (прогнозируемый год)
USD 2,490.06 Million
Diagram CAGR
%
Diagram Основные игроки рынка
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Рынок заболеваний, связанных с IgG4, в Северной Америке, по типу заболевания (аутоиммунный панкреатит (AIP) типа 1 (связанный с IgG4), ретроперитонеальный фиброз, тубулоинтерстициальный нефрит (TIN), связанный с IgG4, склерозирующий холангит, связанный с IgG4, дакриоаденит и сиалоаденит, связанный с IgG4, пахименингит, связанное с IgG4 заболевание щитовидной железы, концентрация IgG4 в сыворотке и другие), тип (диагностика и лечение), способ введения (парентеральный, пероральный и другие), конечный пользователь ( больницы, специализированные клиники и другие), канал сбыта (больничная аптека, розничная аптека, интернет-аптека и другие), страна (США, Канада и Мексика) Тенденции отрасли и прогноз до 2028 года

Рынок заболеваний, связанных с IgG4 в Северной АмерикеАнализ рынка и идеи: рынок заболеваний, связанных с IgG4, в Северной Америке

Ожидается, что рынок заболеваний, связанных с IgG4, в Северной Америке значительно вырастет в период с 2021 по 2028 год. По данным Data Bridge Market Research, рынок заболеваний, связанных с IgG4, в Северной Америке растет со среднегодовым темпом роста 4,1% в прогнозируемый период с 2021 по 2028 год и, как ожидается, достигнет 2 490,06 млн долларов США к 2028 году по сравнению с 1 856,39 млн долларов США в 2020 году. Основными ожидаемыми драйверами роста рынка в прогнозируемый период являются рост инноваций и технологий, а также доступность передовых технологий в сфере здравоохранения.

Все больше людей страдают от заболеваний, связанных с IgG4, что требует высокоэффективного и передового лечения для минимизации риска. Системы здравоохранения нуждаются в высокосовременных препаратах для многочисленных различных типов заболеваний, связанных с IgG4, во время лечения пациентов. Поэтому основные участники рынка уделяют большое внимание запуску и одобрению продуктов. Кроме того, правительство и регулирующие органы поддерживают участников рынка в процессе одобрения продуктов.

Растущий технологический прогресс на рынке заболеваний, связанных с IgG4, в Северной Америке выступает в качестве драйвера. Рост расходов на здравоохранение может стать возможностью для роста рынка. Появление COVID-19 задержало диагностику заболевания, что создало проблему для рынка. Ожидается, что высокая стоимость лечения будет препятствовать росту рынка в прогнозируемый период.

Отчет о рынке заболеваний, связанных с IgG4, в Северной Америке содержит подробную информацию о доле рынка, новых разработках и анализе продуктового портфеля, влиянии внутренних и локальных игроков рынка, анализирует возможности с точки зрения новых источников дохода, изменений в рыночных правилах, одобрений продуктов, стратегических решений, запусков продуктов, географических расширений и технологических инноваций на рынке. Чтобы понять анализ и рыночный сценарий, свяжитесь с нами для получения аналитического обзора; наша команда поможет вам создать решение по влиянию на доход для достижения желаемой цели.   

Рынок заболеваний, связанных с IgG4 в Северной АмерикеМасштаб и размер рынка заболеваний, связанных с IgG4, в Северной Америке

The North America IgG4-related disease market is segmented based on disease type, type, route of administration, end-user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of disease type, the North America IgG4-related disease market is segmented into type 1 (IgG4-related) autoimmune pancreatitis (AIP), retroperitoneal fibrosis, IgG4-related tubulointerstitial nephritis (TIN), igg4-related sclerosing cholangitis IgG4-related dacryoadenitis and sialadenitis, IgG4-related pachymeningitis, IgG4-related thyroid disease, serum IgG4 concentration, and others.  In 2021, the IgG4-related dacryoadenitis and sialadenitis segment is expected to dominate the market due to the approval of new biosimilar drugs by the FDA.
  • On the basis of type, the North America IgG4-related disease market is segmented into diagnostic and treatment. In 2021, the diagnostics segment is expected to dominate the market because of surging cases of IgG4-related diseases.
  • On the basis of route of administration, the North America IgG4-related disease market is segmented into oral, parenteral, and others. In 2021, the parenteral segment is expected to dominate the market because it is the most effective mode of administration with better patient compliance.
  • On the basis of end-user, the North America IgG4-related disease market is segmented into hospitals, specialty clinics, others. In 2021, the hospital's segment is expected to dominate the market because of rising healthcare expenditure.
  • On the basis of distribution channel, the North America IgG4-related disease market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others. In 2021, the hospital pharmacy segment is expected to dominate the market owing to increasing R & D activities.

North America IgG4-Related Disease Market Country Level Analysis

The North America IgG4-related disease market is analyzed, and market size information is provided based on disease type, type, route of administration, end-user, and distribution channel. The countries covered in the North America IgG4-related disease market report are U.S., Canada, Mexico.

North America is expected to dominate the North America IgG4-related disease market due to rising technological advancement in the region. The U.S. dominates the market and leads the growth in the North America IgG4-related disease market due to rising awareness of IgG4-related disease.

Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North American brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.  

Rising healthcare expenditure and escalation in innovations and technologies in the North America igG4-related disease market are creating new opportunities for players

IgG4-related disease by disease type segment in the U.S. is expected to grow at the highest rate, and it is dominating the North American region in the forecast period of 2021 to 2028 because of rising innovation and technologies.

North America IgG4-related disease market also provides you with detailed market analysis for every country's growth in a particular industry with the market sales, impact of advancement in the market, and changes in regulatory scenarios with their support for the North America IgG4-related disease market. The data is available for the historical period 2010 to 2019. 

Competitive Landscape and North America IgG4-Related Disease Market Share Analysis

North America IgG4-related disease market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, and technology lifeline curve. The above data points are only related to the companies’ focus on the North America IgG4-related disease market.

Major players covered in the report are Hikma Pharmaceuticals PLC, Zydus Cadila, Lannett, Sun Pharmaceutical Industries Ltd, Baxter, Viatris Inc., Amgen Inc., Sandoz International GmbH (a subsidiary of Novartis AG), Fresenius Kabi USA (a subsidiary of Fresenius SE & Co. KGaA), Pfizer Inc., Cipla Inc., Celltrion Healthcare Co., Ltd., Antares Pharma, Amneal Pharmaceuticals LLC, Accord-UK Ltd., Genentech, Inc., Ingenus Pharmaceuticals, STI PHARMA, SEBELA PHARMACEUTICAL, ANI Pharmaceuticals, Inc., among others domestic and North America players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launches and agreements are also initiated by the companies worldwide, further accelerating the North America IgG4-related disease market.

For instance,

  • In March 2021, STI Pharma announced the launch of a new website with better features and design. This has increased the customer base and sales and demand of the product in the market
  • В августе 2021 года компания MediPrint™ Ophthalmics объявила о новом корпоративном брендинге и новом веб-сайте. Новый веб-сайт демонстрирует инновационную фармацевтическую миссию предприятия и его команды по защите зрения. Он содержит информацию о том, как компания MediPrint Ophthalmics изначально разрабатывает высокоинновационное решение для значительной неудовлетворенной потребности в глаукоме. Это увеличило продажи и спрос на продукт и способствует получению дохода.


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Интерактивная панель анализа данных
  • Панель анализа компании для возможностей с высоким потенциалом роста
  • Доступ аналитика-исследователя для настройки и запросов
  • Анализ конкурентов с помощью интерактивной панели
  • Последние новости, обновления и анализ тенденций
  • Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов
Запросить демонстрацию

Содержание

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF NORTH AMERICA IGG4-RELATED DISEASE MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET APPLICATION COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL'S MODEL

4.2 PORTER'S 5 FORCES

5 REGIONAL SUMMARY

5.1 SUMMARY WRITE UP (NORTH AMERICA)

5.1.1 OVERVIEW

5.2 SUMMARY WRITE UP (EUROPE)

5.2.1 OVERVIEW

5.3 SUMMARY WRITE UP (ASIA-PACIFIC)

5.3.1 OVERVIEW

5.4 SUMMARY WRITE UP (SOUTH AMERICA)

5.4.1 OVERVIEW

5.5 SUMMARY WRITE UP (MIDDLE EAST AND AFRICA)

5.5.1 OVERVIEW

6 EPIDEMIOLOGY

7 REGULATORY GUIDELINES FOR NORTH AMERICA IGG4-RELATED DISEASE MARKET

7.1 U.S. REGULATORY FRAMEWORK

7.2 EUROPE REGULATORY FRAMEWORK

7.3 JAPAN REGULATORY FRAMEWORK

8 PIPELINE ANALYSIS

9 MARKET OVERVIEW

9.1 DRIVERS

9.1.1 RISING AWARENESS ABOUT IMMUNOGLOBULIN G4-RELATED DISEASE (IGG4-RD)

9.1.2 ESCALATION IN INNOVATION AND TECHNOLOGIES

9.1.3 INCREASE IN RESEARCH & DEVELOPMENT INVESTMENT FOR DRUG DISCOVERY

9.2 RESTRAINTS

9.2.1 HIGH COST OF IMMUNOGLOBULIN G4-RELATED DISEASE (IGG4-RD) TREATMENT

9.2.2 ADVERSE EFFECTS ASSOCIATED WITH TREATMENT

9.3 OPPORTUNITIES

9.3.1 RISING EXPENDITURE ON HEALTHCARE

9.3.2 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS

9.3.3 GOVERNMENT FUNDING FOR RESEARCH PURPOSE

9.4 CHALLENGE

9.4.1 DIFFICULT DIAGNOSIS AND MANGEMENT OF THE DISEASE

10 IMPACT OF COVID 19 PANDEMIC ON THE MARKET

10.1 PRICE IMPACT

10.2 IMPACT ON SUPPLY CHAIN

10.3 IMPACT ON DEMAND

10.4 STRATEGIC DECISIONS FOR MANUFACTURERS

10.5 CONCLUSION

11 NORTH AMERICA IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE

11.1 OVERVIEW

11.2 IGG4-RELATED DACRYOADENITIS AND SIALADENITIS

11.3 RETROPERITONEAL FIBROSIS

11.4 IGG4-RELATED THYROID DISEASE

11.5 IGG4-RELATED TUBULOINTERSTITIAL NEPHRITIS (TIN)

11.6 IGG4-RELATED SCLEROSING CHOLANGITIS

11.7 TYPE 1 (IGG4-RELATED) AUTOIMMUNE PANCREATITIS (AIP)

11.8 IGG4-RELATED PACHYMENINGITIS

11.9 OTHERS

12 NORTH AMERICA IGG4-RELATED DISEASE MARKET, BY TYPE

12.1 OVERVIEW

12.2 DIAGNOSTIC

12.2.1 IMAGING

12.2.1.1 COMPUTED TOMOGRAPHY (CT)

12.2.1.2 MAGNETIC RESONANCE IMAGING (MRI)

12.2.1.3 PET/CT

12.2.1.4 OTHERS

12.2.2 LABORATORY TESTING (SERUM IGG4 CONCENTRATION)

12.2.3 FLOW CYTOMETRY

12.2.4 OTHERS

12.3 TREATMENT

12.3.1 RITUXIMAB

12.3.2 CYCLOPHOSPHAMIDE

12.3.3 METHOTREXATE

12.3.4 STEROIDS

12.3.4.1 Methylprednisolone

12.3.4.2 Prednisolone

12.3.4.3 others

12.3.5 AZATHIOPRINE

12.3.6 OTHERS

13 NORTH AMERICA IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION

13.1 OVERVIEW

13.2 PARENTERAL

13.3 ORAL

13.4 OTHERS

14 NORTH AMERICA IGG4-RELATED DISEASE MARKET, BY END USER

14.1 OVERVIEW

14.2 HOSPITALS

14.3 SPECIALTY CLINICS

14.4 OTHERS

15 NORTH AMERICA IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 HOSPITAL PHARMACY

15.3 RETAIL PHARMACY

15.4 ONLINE PHARMACY

15.5 OTHERS

16 NORTH AMERICA IGG4-RELATED DISEASE MARKET, BY REGION

16.1 NORTH AMERICA

16.1.1 U.S.

16.1.2 CANADA

16.1.3 MEXICO

17 NORTH AMERICA IGG4-RELATED DISEASE MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

18 SWOT ANALYSIS

19 COMPANY PROFILE

19.1 PFIZER INC.

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 COMPANY SHARE ANALYSIS

19.1.4 PRODUCT PORTFOLIO

19.1.5 RECENT DEVELOPMENT

19.2 AMGEN INC.

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUE ANALYSIS

19.2.3 COMPANY SHARE ANALYSIS

19.2.4 PRODUCT PORTFOLIO

19.2.5 RECENT DEVELOPMENT

19.3 GENENTECH, INC.

19.3.1 COMPANY SNAPSHOT

19.3.2 COMPANY SHARE ANALYSIS

19.3.3 PRODUCT PORTFOLIO

19.3.4 RECENT DEVELOPMENT

19.4 CELLTRION HEALTHCARE CO., LTD.

19.4.1 COMPANY SNAPSHOT

19.4.2 REVENUE ANALYSIS

19.4.3 COMPANY SHARE ANALYSIS

19.4.4 PRODUCT PORTFOLIO

19.4.5 RECENT DEVELOPMENT

19.5 SANDOZ INTERNATIONAL GMBH (A SUBSIDIARY OF NOVARTIS AG)

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 COMPANY SHARE ANALYSIS

19.5.4 PRODUCT PORTFOLIO

19.5.5 RECENT DEVELOPMENT

19.6 ACCORD-UK LTD.

19.6.1 COMPANY SNAPSHOT

19.6.2 REVENUE ANALYSIS

19.6.3 PRODUCT PORTFOLIO

19.6.4 RECENT DEVELOPMENT

19.7 AMNEAL PHARMACEUTICALS LLC

19.7.1 COMPANY SNAPSHOT

19.7.2 REVENUE ANALYSIS

19.7.3 PRODUCT PORTFOLIO

19.7.4 RECENT DEVELOPMENTS

19.8 ANI PHARMACEUTICALS, INC.

19.8.1 COMPANY SNAPSHOT

19.8.2 REVENUE ANALYSIS

19.8.3 PRODUCT PORTFOLIO

19.8.4 RECENT DEVELOPMENT

19.9 ANTARES PHARMA

19.9.1 COMPANY SNAPSHOT

19.9.2 REVENUE ANALYSIS

19.9.3 PRODUCT PORTFOLIO

19.9.4 RECENT DEVELOPMENT

19.1 BAXTER

19.10.1 COMPANY SNAPSHOT

19.10.2 REVENUE ANALYSIS

19.10.3 PRODUCT PORTFOLIO

19.10.4 RECENT DEVELOPMENT

19.11 CIPLA INC.

19.11.1 COMPANY SNAPSHOT

19.11.2 REVENUE ANALYSIS

19.11.3 PRODUCT PORTFOLIO

19.11.4 RECENT DEVELOPMENTS

19.12 FRESENIUS KABI USA (A SUBSIDIARY OF FRESENIUS SE & CO. KGAA)

19.12.1 COMPANY SNAPSHOT

19.12.2 REVENUE ANALYSIS

19.12.3 PRODUCT PORTFOLIO

19.12.4 RECENT DEVELOPMENTS

19.13 HIKMA PHARMACEUTICALS PLC

19.13.1 COMPANY SNAPSHOT

19.13.2 REVENUE ANALYSIS

19.13.3 PRODUCT PORTFOLIO

19.13.4 RECENT DEVELOPMENTS

19.14 INGENUS PHARMACEUTICALS

19.14.1 COMPANY SNAPSHOT

19.14.2 PRODUCT PORTFOLIO

19.14.3 RECENT DEVELOPMENT

19.15 LANNETT

19.15.1 COMPANY SNAPSHOT

19.15.2 REVENUE ANALYSIS

19.15.3 PRODUCT PORTFOLIO

19.15.4 RECENT DEVELOPMENTS

19.16 SEBELA PHARMACEUTICALS

19.16.1 COMPANY SNAPSHOT

19.16.2 PRODUCT PORTFOLIO

19.16.3 RECENT DEVELOPMENT

19.17 STI PHARMA

19.17.1 COMPANY SNAPSHOT

19.17.2 PRODUCT PORTFOLIO

19.17.3 RECENT DEVELOPMENT

19.18 SUN PHARMACEUTICAL INDUSTRIES LTD.

19.18.1 COMPANY SNAPSHOT

19.18.2 REVENUE ANALYSIS

19.18.3 PRODUCT PORTFOLIO

19.18.4 RECENT DEVELOPMENT

19.19 VIATRIS INC.

19.19.1 COMPANY SNAPSHOT

19.19.2 REVENUE ANALYSIS

19.19.3 PRODUCT PORTFOLIO

19.19.4 RECENT DEVELOPMENT

19.2 ZYDUS CADILA

19.20.1 COMPANY SNAPSHOT

19.20.2 REVENUE ANALYSIS

19.20.3 PRODUCT PORTFOLIO

19.20.4 RECENT DEVELOPMENT

20 COMPANIES WITH PRODUCTS IN PHASE II AND PHASE III CLINICAL TRIALS

20.1 SANOFI

20.1.1 COMPANY SNAPSHOT

20.1.2 REVENUE ANALYSIS

20.1.3 PRODUCT PORTFOLIO

20.1.4 RECENT DEVELOPMENT

20.2 XENCOR

20.2.1 COMPANY SNAPSHOT

20.2.2 REVENUE ANALYSIS

20.2.3 PRODUCT PORTFOLIO

20.2.4 RECENT DEVELOPMENT

20.3 BRISTOL-MYERS SQUIBB COMPANY

20.3.1 COMPANY SNAPSHOT

20.3.2 REVENUE ANALYSIS

20.3.3 PRODUCT PORTFOLIO

20.3.4 RECENT DEVELOPMENTS

20.4 HORIZON THERAPEUTICS PLC

20.4.1 COMPANY SNAPSHOT

20.4.2 REVENUE ANALYSIS

20.4.3 PRODUCT PORTFOLIO

20.4.4 RECENT DEVELOPMENT

21 QUESTIONNAIRE

22 RELATED REPORTS

Список таблиц

TABLE 1 NORTH AMERICA IGG4-RELATED DISEASE MARKET, PIPELINE ANALYSIS

TABLE 2 NORTH AMERICA IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)

TABLE 3 NORTH AMERICA IGG4-RELATED DACRYOADENITIS AND SIALADENITIS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 4 NORTH AMERICA RETROPERITONEAL FIBROSIS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 5 NORTH AMERICA IGG4-RELATED THYROID DISEASE IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 6 NORTH AMERICA IGG4-RELATED TUBULOINTERSTITIAL NEPHRITIS (TIN) IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 7 NORTH AMERICA IGG4-RELATED SCLEROSING CHOLANGITIS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 8 NORTH AMERICA TYPE 1 (IGG4-RELATED) AUTOIMMUNE PANCREATITIS (AIP) IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 9 NORTH AMERICA IGG4-RELATED PACHYMENINGITIS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 10 NORTH AMERICA OTHERS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 11 NORTH AMERICA IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 12 NORTH AMERICA DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 13 NORTH AMERICA DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 14 NORTH AMERICA IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 15 NORTH AMERICA TREATMENT IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 16 NORTH AMERICA TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 17 NORTH AMERICA STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 18 NORTH AMERICA IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)

TABLE 19 NORTH AMERICA PARENTERAL IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 20 NORTH AMERICA ORAL IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 21 NORTH AMERICA OTHERS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 22 NORTH AMERICA IGG4-RELATED DISEASE MARKET, BY END USERS, 2019-2028 (USD THOUSAND)

TABLE 23 NORTH AMERICA HOSPITALS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 24 NORTH AMERICA SPECIALTY CLINICS IN NORTH AMERICA IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 25 NORTH AMERICA OTHERS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 26 NORTH AMERICA IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)

TABLE 27 NORTH AMERICA HOSPITAL PHARMACY IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 28 NORTH AMERICA RETAIL PHARMACY IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 29 NORTH AMERICA ONLINE PHARMACY IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 30 NORTH AMERICA OTHERS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 31 NORTH AMERICA IGG4-RELATED DISEASE MARKET, BY COUNTRY, 2019-2028 (USD THOUSAND)

TABLE 32 NORTH AMERICA IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)

TABLE 33 NORTH AMERICA IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 34 NORTH AMERICA DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 35 NORTH AMERICA IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 36 NORTH AMERICA TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 37 NORTH AMERICA STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 38 NORTH AMERICA IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)

TABLE 39 NORTH AMERICA IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)

TABLE 40 NORTH AMERICA IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)

TABLE 41 U.S. IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)

TABLE 42 U.S. IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 43 U.S. DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 44 U.S. IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 45 U.S. TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 46 U.S. STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 47 U.S. IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)

TABLE 48 U.S. IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)

TABLE 49 U.S. IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)

TABLE 50 CANADA IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)

TABLE 51 CANADA IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 52 CANADA DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 53 CANADA IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 54 CANADA TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 55 CANADA STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 56 CANADA IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)

TABLE 57 CANADA IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)

TABLE 58 CANADA IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)

TABLE 59 MEXICO IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)

TABLE 60 MEXICO IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 61 MEXICO DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 62 MEXICO IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 63 MEXICO TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 64 MEXICO STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)

TABLE 65 MEXICO IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)

TABLE 66 MEXICO IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)

TABLE 67 MEXICO IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)

Список рисунков

FIGURE 1 NORTH AMERICA IGG4-RELATED DISEASE MARKET : SEGMENTATION

FIGURE 2 NORTH AMERICA IGG4-RELATED DISEASE MARKET : DATA TRIANGULATION

FIGURE 3 NORTH AMERICA IGG4-RELATED DISEASE MARKET : DROC ANALYSIS

FIGURE 4 NORTH AMERICA IGG4-RELATED DISEASE MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA IGG4-RELATED DISEASE MARKET : COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA IGG4-RELATED DISEASE MARKET : INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA IGG4-RELATED DISEASE MARKET : DBMR MARKET POSITION GRID

FIGURE 8 NORTH AMERICA IGG4-RELATED DISEASE MARKET : MARKET APPLICATION COVERAGE GRID

FIGURE 9 NORTH AMERICA IGG4-RELATED DISEASE MARKET : VENDOR SHARE ANALYSIS

FIGURE 10 NORTH AMERICA IGG4-RELATED DISEASE MARKET : SEGMENTATION

FIGURE 11 INCREASING AWARENESS FOR IGG4-RELATED DISEASES AND RISING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE NORTH AMERICA IGG4-RELATED DISEASE MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 12 IGG4-RELATED DACRYOADENITIS AND SIALADENITIS IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA IGG4-RELATED DISEASE MARKET IN 2021 & 2028

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: NORTH AMERICA IGG4-RELATED DISEASE MARKET

FIGURE 14 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY DISEASE TYPE, 2020

FIGURE 15 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY DISEASE TYPE, 2019-2028 (USD THOUSAND)

FIGURE 16 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY DISEASE TYPE, CAGR (2021-2028)

FIGURE 17 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 18 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY TYPE, 2020

FIGURE 19 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY TYPE, 2019-2028 (USD THOUSAND)

FIGURE 20 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY TYPE, CAGR (2021-2028)

FIGURE 21 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY TYPE, LIFELINE CURVE

FIGURE 22 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY ROUTE OF ADMINISTRATION, 2020

FIGURE 23 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)

FIGURE 24 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)

FIGURE 25 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 26 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY END USERS, 2020

FIGURE 27 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY END USERS, 2019-2028 (USD THOUSAND)

FIGURE 28 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY END USERS, CAGR (2021-2028)

FIGURE 29 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY END USERS, LIFELINE CURVE

FIGURE 30 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 31 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)

FIGURE 32 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY DISTRIBUTION CHANNEL,CAGR (2021-2028)

FIGURE 33 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 34 NORTH AMERICA IGG4-RELATED DISEASE MARKET: SNAPSHOT (2020)

FIGURE 35 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY COUNTRY (2020)

FIGURE 36 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY COUNTRY (2021 & 2028)

FIGURE 37 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY COUNTRY (2020 & 2028)

FIGURE 38 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY DISEASE TYPE (2021-2028)

FIGURE 39 NORTH AMERICA IGG4-RELATED DISEASEMARKET: COMPANY SHARE 2020 (%)

View Detailed Information Right Arrow

Методология исследования

Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.

Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.

Доступна настройка

Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.

Часто задаваемые вопросы

The market is segmented based on North America IgG4-Related Disease Market, By Disease Type (Type 1 (IgG4-Related) Autoimmune Pancreatitis (AIP), Retroperitoneal Fibrosis, IgG4-Related Tubulointerstitial Nephritis (TIN), IgG4-Related Sclerosing Cholangitis IgG4-Related Dacryoadenitis and Sialadenitis, IgG4-Related Pachymeningitis, IgG4-Related Thyroid Disease, Serum IgG4 Concentration, and Others), Type (Diagnostic and Treatment), Route of Administration (Parenteral, Oral and Others), End-User (Hospitals, Specialty Clinics, and Others) Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), Country (U.S., Canada, and Mexico) Industry Trends and Forecast to 2028 .
The North America Igg4 Related Disease Market size was valued at USD 1856.39 USD Million in 2020.
The North America Igg4 Related Disease Market is projected to grow at a CAGR of 4.1% during the forecast period of 2021 to 2028.